Kinoxis Therapeutics

Kinoxis Therapeutics is an early-stage biotechnology company based in Australia, dedicated to developing a range of novel therapeutic compounds for the treatment of substance use disorders and other central nervous system diseases. The company has licensed these compounds from the University of Sydney, and its lead candidate has demonstrated strong anti-addiction and prosocial effects in many different animal models, currently undergoing preclinical testing.